Goodwin Advises Biotheus in Agreement to Be Acquired by BioNTech for $800 Million Upfront and $150 Million in Milestones
November 16, 2024
November 16, 2024
BOSTON, Massachusetts, Nov. 16 -- Goodwin, a law firm, issued the following news release:
The Goodwin Life Sciences and M&A team advised Biotheus on the signing of a definitive agreement for its acquisition by BioNTech (Nasdaq: BNTX). Under the terms of the agreement, BioNTech will pay Biotheus shareholders an upfront consideration of $800 million, predominantly in cash, with a small portion in American depositary shares, to acquire 100% of the issued share capital, subject to c . . .
The Goodwin Life Sciences and M&A team advised Biotheus on the signing of a definitive agreement for its acquisition by BioNTech (Nasdaq: BNTX). Under the terms of the agreement, BioNTech will pay Biotheus shareholders an upfront consideration of $800 million, predominantly in cash, with a small portion in American depositary shares, to acquire 100% of the issued share capital, subject to c . . .